These findings confirm that, at least in an in vitro setting, the use of AP-1 inhibitors represents a valuable strategy in cancer [64, 65] and corroborate the possibility that Fra-2 is amenable for targeted therapy approaches [6, 66]. This evidence concerns the gene JUN and cancer.